Page 85 - MSU Digital Book
P. 85
49. Kim JE, Han A, Lee H, Ha J, Kim YS, Han SS. Impact of Pneumocystis jirovecii
pneumonia on kidney transplant outcome. BMC Nephrol. 2019;20:212.
50. Hochleitner BW, Bösmüller C, Nehoda H, Frühwirt M, Simma B, Ellemunter H, et
al. Increased tacrolimus levels during diarrhea. Transpl Int. 2001;14:230-3.
51. Tatro D. Drug Interaction Facts. Wolters Kulwer Health. Missouri.US. 2014.
52. Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC. Can new-onset diabetes
after kidney transplant be prevented? Diabetes Care. 2013;36:1406-12.
53. Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD. Risk factors associated
with post-kidney transplant malignancies: an article from the Cancer-Kidney Inter-
national Network. Clin Kidney J. 2018;11:315-29.
54. Ativitavas T, Jirasiritham S, Ngorsakun P, Pipatpannawong K, Mavichak V. Malignan-
cies in renal transplant patients: 15 years experience in Thailand. Transplant Proc.
2008;40:2403-4.
55. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al.
Drug dosing consideration in patients with acute and chronic kidney disease-a
clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney
Int. 2011;80:1122-37.
56. Shah S, Verma P. Overview of pregnancy in renal transplant patients. Int J Nephrol.
2016;2016:4539342.
57. American Pharmacist Association. Drug information handbook with international
trade names index. 25th ed. Hudson, Ohio: Lexi-Comp; 2016.
58. Kim H, Jeong JC, Yang J, Yang WS, Ahn C, Han DJ, et al. The optimal therapy of
calcineurin inhibitors for pregnancy in kidney transplantation. Clin Transplant.
2015;29:142-8.
์
�
ิ
ึ
ั
่
้
59. รู้าคาอ�างองจดซ้อปกี่ต้ (ยา). ศึ้นยข�อม้ลขาวสารู้ด�านเวช้ภูณีฑ์์ กี่รู้ะทำรู้วงสาธารู้ณีส้ข. [เข�าถ่ง 30
ิ
ั
มถ่้นายน 2564]. จากี่: http://dmsic.moph.go.th/index/drugsearch/1.
ิ
60

